Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s State FDA Enforces New Rules For Traditional Chinese Medicine Registration

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA introduced new supplementary requirements for registering traditional Chinese medicine Jan. 8, to separate the process from western drug registration

You may also be interested in...



Traditional Chinese Medicines Seen As Global Growth Opportunity

HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines

Traditional Chinese Medicines Seen As Global Growth Opportunity

HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines

China Shenghuo Gains Foothold In U.S. Market With TCM Products

SHANGHAI - China Shenghuo Pharmaceutical will launch its new traditional Chinese medicine-based 12Ways Skin Care products in the U.S. during the first quarter of 2008, the company announced Feb. 7

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel